Chronoscale Holdings Corp current report, 28 December 2015

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on December 28, 2015. The report details the consummation of a registered direct offering of securities.

Key Financial Metrics

  • Gross Proceeds: $15 million.
  • Securities Issued: 15,000 shares of Series A Convertible Preferred Stock and warrants to purchase 14,851,486 shares of common stock.
  • Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these specific operational or balance sheet metrics.

Material Changes

The primary material change is the increase in capital raised through the sale of preferred stock and warrants. The company intends to deploy these funds to accelerate product adoption and development.

Guidance, Outlook, and Risks

Use of Proceeds

  • Investments in clinical, sales, and marketing initiatives for the Ekso exoskeleton in the rehabilitation market.
  • Research, development, and commercialization of a robotic exoskeleton for home use.
  • Development and commercialization of able-bodied exoskeletons for industrial use.
  • General corporate purposes.

Risks and Contingencies

The filing includes standard forward-looking statement disclaimers. Key risks identified include:

  • Inability to obtain adequate financing.
  • Significant time and resources required for product development.
  • Failure to achieve broad market acceptance.
  • Adverse results in future clinical studies.
  • Failure to obtain or maintain patent protection or regulatory approval.
  • Lack of product diversification and increased competition.

Investor Verification Checklist

  • Verify the exact terms of the Series A Convertible Preferred Stock and the warrant exercise price.
  • Confirm the timeline for the clinical studies and regulatory approvals mentioned as risks.
  • Review the company's cash burn rate to assess if the $15 million proceeds are sufficient for the stated development goals.
  • Check for any dilution impact on existing common shareholders from the warrant issuance.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.